Acumen Pharma (ABOS): Prognoz qilingan narxning foydaga nisbati
Alzheimer terapevtikasining muvaffaqiyatsiz bo'lish ehtimoli yuqoriligi va R&D xarajatlari moliyaviy beqarorlikni yuzaga keltirmoqda, bu esa Acumen Pharmaceuticals (ABOS) uchun kutilayotgan P/E ko'rsatkichi bilan aks etgan bo'lib, ushbu raqam 0.00 atrofida qolmoqda. Biroq, 2-fazaning muvaffaqiyati va Big Pharma kompaniyalarining M&A kelishuvlariga bo'lgan qiziqishi ushbu xavflarni yumshatadi. Nevrologlarning Acumen Pharmaceuticals ilmiy brendiga bo'lgan kuchli ishonchi aktivning uzoq muddatli salohiyatini tasdiqlaydi.
Acumen Pharmaceuticals, Inc (ABOS) - koʻrsatkichlar kesimi va moliyaviy hisobotlar
- kotirovkalar va tahlilchilar prognozi:
- birja kapitallashuvi ma'lumotlari:
- emitentning balans qiymati statistikasi:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning xususiy kapitalga nisbati Acumen Pharmaceuticals|ABOS - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Qisqa muddatli qarzning o'z kapitaliga nisbati Acumen Pharmaceuticals|ABOS - Jamlangan qarz majburiyatlari|Qarzning balans kapitallashuviga nisbati Acumen Pharmaceuticals Inc.|ABOS - Uzoq muddatli majburiyatlar|Kompaniyaning qisqa muddatli qarzlari Acumen Pharmaceuticals|Tezkor likvidlik koeffitsiyenti acumenpharm.com
- kompaniyaning daromadliligi va baholash multiplikatorlari ko'rsatkichlari:
ABOS - Sof foyda|Kutilayotgan foyda Acumen Pharmaceuticals|ABOS - Kompaniya qiymatining sof foydaga nisbati|Kelajakdagi narxning foydaga nisbati Acumen Pharma|ABOS - Narx-foyda va o‘sish multiplikatori|EV/EBITDA multiplikatori Acumen Pharmaceuticals Inc.|ABOS - EBITDA operatsion foydasi|Bir aksiya uchun sof foyda (EPS TTM) Acumen Pharmaceuticals|ABOS - So'nggi 12 oy davomida bir aksiya uchun sof foyda|Choraklik EPS foyda o'sishi acumenpharm.com|ABOS - Joriy yilda bir aksiya uchun foydaning o'sish sur'ati|Keyingi yil uchun bir aksiya uchun kutilayotgan foyda o'sishi Acumen Pharmaceuticals
Fundamental baholash:ABOS Acumen Pharmaceuticals, Inc.
Forward P/E joriy bozor kapitalizatsiyasining kutilayotgan sof foydaga nisbatini aks ettiradi, bu esa investorlarga kelajakdagi daromadlar qiymatini va aktivning makroiqtisodiy zarbalarga chidamliligini baholash imkonini beradi. Acumen Pharmaceuticals (ABOS) kompaniyasining kelajakdagi P/E darajasidagi o'zgarishlarni tahlil qilish orqali, Altsgeymerga qarshi dori ishlab chiqish bo'yicha strategik R&D alyansi moliyaviy risklarni qanday kamaytirishi va Acumen Pharmaceuticals uchun kapitalning adolatli qiymatini qanday shakllantirishi ko'rinadi.
Acumen Pharmaceuticals raqobatchilari tahlili
Forvard P/E multiplikatori BIIB|Prognoz qilingan narxning foydaga nisbati Neurocrine NBIX|Regencell - Prognoz qilingan narxning foydaga nisbati|Forvard P/E multiplikatori Axsome Corp AXSM|ACAD - Kelajakdagi narxning foydaga nisbati|xenon-pharma.com (XENE) - Prognoz qilingan narxning foydaga nisbati|VKTX: Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Supernus Pharmaceuticals, Inc. (SUPN)|Kelajakdagi narxning foydaga nisbati Catalyst Pharmaceuticals Inc|Narxning kelajakdagi foydaga nisbati DNLI (Denali Corp)|Prognoz qilingan narxning foydaga nisbati HRMY (Harmony Biosciences)|BHVN (biohavenpharma.com) - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Amylyx Pharmaceuticals, Inc. AMLX|TRVI (Trevi Therapeutics Inc) - Narxning kutilayotgan foydaga nisbati|Praxis Medicines - Forvard P/E multiplikatori|Kelajakdagi narx-foyda multiplikatori AVXL (Anavex Life Sciences Corp)|CBLL: Forvard P/E multiplikatori|Prothena (PRTA) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Alector Inc.|ANNX: Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Omeros Corporation (OMER)|Prognoz qilingan narxning foydaga nisbati Neurogene Therapeutics NGNE|Forvard P/E multiplikatori ACIU (AC Immune)|Forvard P/E multiplikatori voyagertherapeutics.com VYGR|Neumora Therapeutics, Inc. - Forvard P/E multiplikatori|Scilex Holding (SCLX) - Prognoz qilingan narxning foydaga nisbati|TVGN: Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Alpha Cognition Inc. (ACOG)|Prognoz qilingan narxning foydaga nisbati CGTX|Forvard P/E multiplikatori inhibikase.com|Prognoz qilingan narxning foydaga nisbati SAVA (Cassava Sciences)|Kapitalizatsiyaning kelajakdagi foydaga nisbati ASRT|Forvard P/E multiplikatori COYA (Coya Therapeutics)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati VistaGen Therapeutics, Inc. (VTGN)|Ovid Rx - Forvard P/E multiplikatori|cervomed.com (CRVO) - Prognoz qilingan narxning foydaga nisbati|ATHE: Forvard P/E multiplikatori|Clene (CLNN) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati PepGen Inc|Kelajakdagi narxning foydaga nisbati JUNS|Kelajakdagi narxning foydaga nisbati Relmada Therapeutics (RLMD)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati annovisbio.com|Forvard P/E multiplikatori GRCE (Grace Therapeutics)|Forvard P/E multiplikatori Firefly Neuroscience, Inc. AIFF|ANEW Medical, Inc. - Forvard P/E multiplikatori|NRSN: Kelajakdagi narxning foydaga nisbati|Reviva Pharmaceuticals (RVPH) - Kelajakdagi narxning foydaga nisbati|Prognoz qilingan narx-foyda nisbati MetaVia (MTVA)|Kelajakdagi narxning foydaga nisbati NeurAxis|Helius Medical Technologies Inc. (HSDT) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Passage Bio, Inc. (PASG)|bionomics.com.au - Narxning kelajakdagi foydaga nisbati|Forvard P/E multiplikatori NERV (Minerva Neurosciences)|athira.com (ATHA) - Prognoz qilingan narx-foyda nisbati|ADXN: Prognoz qilingan narxning foydaga nisbati|ALZN - Forvard P/E multiplikatori|cyclerion.com (CYCN) - Kelajakdagi narxning foydaga nisbati|Protagenic Therapeutics, Inc. - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Pasithea Therapeutics Corp|Prognoz qilingan narx-foyda nisbati Cortigent Medical CRGT|Forvard P/E multiplikatori ATXI|Forvard P/E multiplikatori Brainstorm Cell Therapeutics Inc. (BCLI)|Forvard P/E multiplikatori CARA (Cara Therapeutics, Inc)|CHRO - Prognoz qilingan narxning foydaga nisbati|ELYM: Prognoz qilingan narxning foydaga nisbati|ITCI - Forvard P/E multiplikatori|Longboard Pharmaceuticals, Inc. (LBPH) - Kelajakdagi narxning foydaga nisbati|Prognoz qilingan narxning foydaga nisbati Marinus Pharmaceuticals Inc|NKGN (NKGen) - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati NeuroBo Pharma NRBO|Kelajakdagi narxning foydaga nisbati Sage Therapeutics, Inc. (SAGE)|synaptogen.com - Narxning kelajakdagi foydaga nisbati|Trevena - Prognoz qilingan narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori VIGL|WENA - Kelajakdagi narxning foydaga nisbati|Narxning kutilayotgan foydaga nisbati CERE
